Annual CFO
-$37.09 M
+$15.33 M+29.24%
December 31, 2023
Summary
- As of February 23, 2025, UBX annual cash flow from operations is -$37.09 million, with the most recent change of +$15.33 million (+29.24%) on December 31, 2023.
- During the last 3 years, UBX annual CFO has risen by +$41.24 million (+52.65%).
- UBX annual CFO is now -126.17% below its all-time high of -$16.40 million, reached on December 31, 2016.
Performance
UBX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$5.19 M
-$609.00 K-13.29%
September 30, 2024
Summary
- As of February 23, 2025, UBX quarterly cash flow from operations is -$5.19 million, with the most recent change of -$609.00 thousand (-13.29%) on September 30, 2024.
- Over the past year, UBX quarterly CFO has increased by +$1.92 million (+27.00%).
- UBX quarterly CFO is now -13.29% below its all-time high of -$4.58 million, reached on June 30, 2024.
Performance
UBX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$22.54 M
+$1.92 M+7.85%
September 30, 2024
Summary
- As of February 23, 2025, UBX TTM cash flow from operations is -$22.54 million, with the most recent change of +$1.92 million (+7.85%) on September 30, 2024.
- Over the past year, UBX TTM CFO has increased by +$18.73 million (+45.39%).
- UBX TTM CFO is now -186.70% below its all-time high of -$7.86 million, reached on March 31, 2017.
Performance
UBX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
UBX Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +29.2% | +27.0% | +45.4% |
| 3 y3 years | +52.6% | +55.8% | +57.0% |
| 5 y5 years | +34.5% | +55.8% | +57.0% |
UBX Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +29.2% | -13.3% | +65.3% | at high | +57.0% |
| 5 y | 5-year | at high | +52.6% | -13.3% | +79.3% | at high | +71.2% |
| alltime | all time | -126.2% | +52.6% | -13.3% | +79.3% | -186.7% | +71.2% |
Unity Biotechnology Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$5.19 M(+13.3%) | -$22.54 M(-7.9%) |
| Jun 2024 | - | -$4.58 M(-11.6%) | -$24.46 M(-21.0%) |
| Mar 2024 | - | -$5.18 M(-31.6%) | -$30.95 M(-16.5%) |
| Dec 2023 | -$37.09 M(-29.2%) | -$7.58 M(+6.5%) | -$37.09 M(-10.1%) |
| Sep 2023 | - | -$7.11 M(-35.8%) | -$41.26 M(-8.3%) |
| Jun 2023 | - | -$11.08 M(-2.1%) | -$45.01 M(-7.7%) |
| Mar 2023 | - | -$11.32 M(-3.7%) | -$48.76 M(-7.0%) |
| Dec 2022 | -$52.41 M(+16.3%) | -$11.75 M(+8.2%) | -$52.41 M(+14.7%) |
| Sep 2022 | - | -$10.86 M(-26.8%) | -$45.69 M(-1.5%) |
| Jun 2022 | - | -$14.84 M(-0.9%) | -$46.39 M(+3.2%) |
| Mar 2022 | - | -$14.97 M(+197.7%) | -$44.94 M(-0.3%) |
| Dec 2021 | -$45.06 M(-42.5%) | -$5.03 M(-56.5%) | -$45.06 M(-20.6%) |
| Sep 2021 | - | -$11.56 M(-13.7%) | -$56.74 M(-9.1%) |
| Jun 2021 | - | -$13.38 M(-11.3%) | -$62.45 M(-8.6%) |
| Mar 2021 | - | -$15.09 M(-9.7%) | -$68.35 M(-12.7%) |
| Dec 2020 | -$78.33 M | -$16.71 M(-3.2%) | -$78.33 M(+1.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | -$17.26 M(-10.5%) | -$77.31 M(+0.6%) |
| Jun 2020 | - | -$19.28 M(-23.1%) | -$76.88 M(-0.0%) |
| Mar 2020 | - | -$25.07 M(+59.8%) | -$76.90 M(+6.2%) |
| Dec 2019 | -$72.42 M(+27.9%) | -$15.69 M(-6.8%) | -$72.42 M(+4.1%) |
| Sep 2019 | - | -$16.83 M(-12.8%) | -$69.54 M(+4.4%) |
| Jun 2019 | - | -$19.30 M(-6.3%) | -$66.59 M(+1.9%) |
| Mar 2019 | - | -$20.60 M(+60.8%) | -$65.34 M(+15.4%) |
| Dec 2018 | -$56.62 M(+47.6%) | -$12.81 M(-7.8%) | -$56.62 M(+2.2%) |
| Sep 2018 | - | -$13.88 M(-23.1%) | -$55.42 M(+9.4%) |
| Jun 2018 | - | -$18.05 M(+51.9%) | -$50.65 M(+19.5%) |
| Mar 2018 | - | -$11.88 M(+2.4%) | -$42.38 M(+10.5%) |
| Dec 2017 | -$38.36 M(+133.9%) | -$11.60 M(+27.2%) | -$38.36 M(+43.4%) |
| Sep 2017 | - | -$9.12 M(-6.7%) | -$26.76 M(+51.7%) |
| Jun 2017 | - | -$9.78 M(+24.4%) | -$17.64 M(+124.4%) |
| Mar 2017 | - | -$7.86 M | -$7.86 M |
| Dec 2016 | -$16.40 M | - | - |
FAQ
- What is Unity Biotechnology annual cash flow from operations?
- What is the all time high annual CFO for Unity Biotechnology?
- What is Unity Biotechnology annual CFO year-on-year change?
- What is Unity Biotechnology quarterly cash flow from operations?
- What is the all time high quarterly CFO for Unity Biotechnology?
- What is Unity Biotechnology quarterly CFO year-on-year change?
- What is Unity Biotechnology TTM cash flow from operations?
- What is the all time high TTM CFO for Unity Biotechnology?
- What is Unity Biotechnology TTM CFO year-on-year change?
What is Unity Biotechnology annual cash flow from operations?
The current annual CFO of UBX is -$37.09 M
What is the all time high annual CFO for Unity Biotechnology?
Unity Biotechnology all-time high annual cash flow from operations is -$16.40 M
What is Unity Biotechnology annual CFO year-on-year change?
Over the past year, UBX annual cash flow from operations has changed by +$15.33 M (+29.24%)
What is Unity Biotechnology quarterly cash flow from operations?
The current quarterly CFO of UBX is -$5.19 M
What is the all time high quarterly CFO for Unity Biotechnology?
Unity Biotechnology all-time high quarterly cash flow from operations is -$4.58 M
What is Unity Biotechnology quarterly CFO year-on-year change?
Over the past year, UBX quarterly cash flow from operations has changed by +$1.92 M (+27.00%)
What is Unity Biotechnology TTM cash flow from operations?
The current TTM CFO of UBX is -$22.54 M
What is the all time high TTM CFO for Unity Biotechnology?
Unity Biotechnology all-time high TTM cash flow from operations is -$7.86 M
What is Unity Biotechnology TTM CFO year-on-year change?
Over the past year, UBX TTM cash flow from operations has changed by +$18.73 M (+45.39%)